Federal contract award
HDTRA124C0014
ORAL BROAD SPECTRUM ANTIVIRAL TLR7 AGONIST FOR TREATMENT OF LASSA FEVER
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | DEFENSE THREAT REDUCTION AGENCY |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AC33 — NATIONAL DEFENSE R&D SERVICES; DEFENSE-RELATED ACTIVITIES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $11.3M |
| Current contract value | $11.3M |
| Potential contract value / ceiling | $23.1M |
| Start date | Jan 30, 2024 |
| Current end date | Aug 31, 2026 |
| Potential end date | Dec 31, 2027 |
| Latest award activity | Apr 20, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 14 of 14 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Apr 20, 2026 | P00012 | $217.5K | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 |
| Jan 22, 2026 | P00011 | $366.3K | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 |
| Dec 12, 2025 | P00010 | $0 | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 |
| Jul 25, 2025 | P00009 | $0 | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 |
| May 20, 2025 | P00008 | $1.4M | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 |
| Apr 30, 2025 | P00007 | $0 | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 |
| Mar 6, 2025 | P00006 | $0 | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 AGONIST FOR TREATMENT OF LASSA FEVER |
| Jan 16, 2025 | P00005 | $0 | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 AGONIST FOR TREATMENT OF LASSA FEVER |
| Nov 19, 2024 | P00004 | $1.4M | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 AGONIST FOR TREATMENT OF LASSA FEVER. |
| Jul 1, 2024 | ARZ999 | $0 | ADDITION/DELETION OF GFP CLAUSES |
| May 22, 2024 | P00003 | $5.2M | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 AGONIST FOR TREATMENT OF LASSA FEVER |
| Apr 17, 2024 | P00002 | $1.8M | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 AGONIST FOR TREATMENT OF LASSA FEVER |
| Feb 14, 2024 | P00001 | $0 | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 AGONIST FOR TREATMENT OF LASSA FEVER |
| Jan 30, 2024 | 0 | $845.6K | ORAL BROAD SPECTRUM ANTIVIRAL TLR7 AGONIST FOR TREATMENT OF LASSA FEVER |
Estimated positioning window
Dec 31, 2026 – Jun 30, 2027
70/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 70/100. Available recorded signals: 65 points.
- Contract end 2027-12-31 (432 days from calculation)
- +25 points
- 84 historical awards in this buyer and category group
- +15 points
- 14 recorded award transactions
- +10 points
- Latest award action: 2026-04-20
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.